Pulmonary Arterial Hypertension
📧 Sign up to get email alerts when something new happens for Pulmonary Arterial Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2013-07-01FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental NDA for Tracleer (bosentan) submitted by Actelion Pharmaceuticals US, Inc.
-
CLINICAL_TRIALS trial_result · 2013-06-19Clinical Trial Update: 6R-BH4 Pulmonary Arterial Hypertension Study [Phase 1]
An early Phase 1 study evaluating 6R-BH4 for pulmonary arterial hypertension has completed. The trial was conducted at Vanderbilt University…
-
CLINICAL_TRIALS trial_result · 2013-06-10Clinical Trial Update: FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH) [Phase 3]
Phase 3 FREEDOM-C study evaluated oral treprostinil in combination with an endothelin receptor antagonist and/or a phosphodiesterase-5 inhib…
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide [Phase 2]
This Phase 2 pilot trial evaluated the safety and performance of the GeNO NITROsyl inhaled nitric oxide delivery system in patients with pul…
-
FDA approval · 2013-06-03FDA Approved: TRACLEER — Supplemental Application (Actelion Pharmaceuticals US, Inc.)
The FDA approved a supplemental application for TRACLEER (bosentan) by Actelion Pharmaceuticals US, Inc., facilitating changes to the drug's…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2013-05-17Clinical Trial Update: Combination Therapy in Pulmonary Arterial Hypertension [Phase 4]
Actelion-sponsored Phase 4 trial evaluating a combination therapy for pulmonary arterial hypertension has completed, with results posted in …
-
CLINICAL_TRIALS trial_result · 2013-05-17Clinical Trial Update: REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management
The REVEAL Registry study evaluating early and long-term management of pulmonary arterial hypertension has completed.
-
FDA approval · 2013-04-30FDA Approved: TYVASO — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for TYVASO (treprostinil) submitted by United Therapeutics Corporation. The exact changes to lab…
-
CLINICAL_TRIALS trial_result · 2013-04-12Clinical Trial Update: Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension [Phase 2, Phase 3]
This update notes a double-blind, randomized trial of bosentan for sarcoidosis-associated pulmonary hypertension across Phase 2 and Phase 3,…
-
CLINICAL_TRIALS trial_result · 2013-04-12Clinical Trial Update: Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension [Phase 4]
Phase 4 clinical trial evaluating inhaled iloprost for sarcoidosis-associated pulmonary hypertension has completed.
-
CLINICAL_TRIALS trial_result · 2013-03-29Clinical Trial Update: Screening for Sleep Hypoxemia in Pulmonary Arterial Hypertension
A clinical trial update indicates completion of a study screening for sleep hypoxemia in patients with pulmonary arterial hypertension.
-
CLINICAL_TRIALS trial_result · 2013-03-18Clinical Trial Update: FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) [Phase 3]
Phase 3 trial update for oral treprostinil as monotherapy in pulmonary arterial hypertension (FREEDOM-M) completed with posted results in 20…
-
CLINICAL_TRIALS trial_result · 2013-03-07Clinical Trial Update: A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension [Phase 4]
This Phase 4 clinical trial update reports completion of a transition study from Flolan (epoprostenol) to Remodulin (treprostinil) in patien…
-
FDA approval · 2013-02-28FDA Approved: SILDENAFIL — Original Application (Amneal Pharmaceuticals of New York LLC)
FDA approves Amneal Pharmaceuticals of New York LLC's generic sildenafil under an original ANDA, for the same indications as the brand produ…
-
CLINICAL_TRIALS trial_result · 2013-02-25Clinical Trial Update: Bosentan and Pulmonary Endothelial Function [NA]
A completed clinical trial evaluated the effects of bosentan on pulmonary endothelial function in patients with pulmonary arterial hypertens…
-
CLINICAL_TRIALS trial_result · 2013-02-20Clinical Trial Update: Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects [Phase 4]
Phase 4 safety evaluation of inhaled treprostinil after transition from inhaled Ventavis in pulmonary arterial hypertension patients; result…
-
CLINICAL_TRIALS trial_result · 2013-02-18Clinical Trial Update: Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs [Phase 3]
A Phase 3 study evaluating the safety and effectiveness of tadalafil for pulmonary arterial hypertension has completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2013-02-15Clinical Trial Update: Iloprost Power Disc-15 in Pulmonary Arterial Hypertension [Phase 3]
A Phase 3 study of Iloprost Power Disc-15 for pulmonary arterial hypertension was terminated, with results posted in 2013.
-
CLINICAL_TRIALS withdrawal · 2013-01-30Clinical Trial Update: FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH) [Phase 3]
The FREEDOM DR trial evaluating oral treprostinil, with or without ERA or PDE-5 inhibitors, for pulmonary arterial hypertension has been wit…
-
FDA approval · 2013-01-16FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for LETAIRIS (ambrisentan) from Gilead Sciences, Inc.
-
CLINICAL_TRIALS trial_result · 2013-01-15Clinical Trial Update: Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension [Phase 3]
Phase 3 clinical trial results for oral UT-15C in pulmonary arterial hypertension have been posted, detailing efficacy and safety outcomes. …
-
CLINICAL_TRIALS trial_result · 2013-01-15Clinical Trial Update: A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) [Phase 3]
This document reports the completion and long-term results of the ambrisentan extension study in patients with pulmonary arterial hypertensi…
-
FDA label_change · 2013-01-10FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)
The FDA approved a supplemental application for Letairis (ambrisentan) filed by Gilead Sciences, likely updating labeling or indications as …
-
FDA approval · 2013-01-07FDA Approved: TYVASO — Supplemental Application (United Therapeutics Corporation)
The FDA approved a supplemental application for TYVASO (treprostinil) submitted by United Therapeutics Corporation.
-
CLINICAL_TRIALS trial_result · 2013-01-07Clinical Trial Update: Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin [Phase 4]
Phase 4 trial update evaluating safety, efficacy and treatment satisfaction in patients with pulmonary arterial hypertension rapidly switche…